152 related articles for article (PubMed ID: 28775148)
1. The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
Zanini E; Louis LS; Antony J; Karali E; Okon IS; McKie AB; Vaughan S; El-Bahrawy M; Stebbing J; Recchi C; Gabra H
Mol Cancer Ther; 2017 Oct; 16(10):2246-2256. PubMed ID: 28775148
[TBL] [Abstract][Full Text] [Related]
2. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.
McKie AB; Vaughan S; Zanini E; Okon IS; Louis L; de Sousa C; Greene MI; Wang Q; Agarwal R; Shaposhnikov D; Wong JL; Gungor H; Janczar S; El-Bahrawy M; Lam EW; Chayen NE; Gabra H
Cancer Discov; 2012 Feb; 2(2):156-71. PubMed ID: 22585860
[TBL] [Abstract][Full Text] [Related]
3. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB; Garrett JT; Estrada MV; Moore PD; Ericsson PG; Koch JP; Langley E; Singh S; Kim PS; Frampton GM; Sanford E; Owens P; Becker J; Groseclose MR; Castellino S; Joensuu H; Huober J; Brase JC; Majjaj S; Brohée S; Venet D; Brown D; Baselga J; Piccart M; Sotiriou C; Arteaga CL
Clin Cancer Res; 2017 Aug; 23(15):4323-4334. PubMed ID: 28381415
[No Abstract] [Full Text] [Related]
4. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
5. Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.
Antony J; Zanini E; Birtley JR; Gabra H; Recchi C
Cancer Gene Ther; 2021 Feb; 28(1-2):18-26. PubMed ID: 32595215
[TBL] [Abstract][Full Text] [Related]
6. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
Borrero-García LD; Del Mar Maldonado M; Medina-Velázquez J; Troche-Torres AL; Velazquez L; Grafals-Ruiz N; Dharmawardhane S
BMC Cancer; 2021 Jun; 21(1):652. PubMed ID: 34074257
[TBL] [Abstract][Full Text] [Related]
7. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
[TBL] [Abstract][Full Text] [Related]
8. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
9. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
Brady SW; Zhang J; Tsai MH; Yu D
Cancer Biol Ther; 2015; 16(3):402-11. PubMed ID: 25692408
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
Liu L; Shi H; Liu Y; Anderson A; Peterson J; Greger J; Martin AM; Gilmer TM
Mol Cancer Ther; 2011 Mar; 10(3):518-30. PubMed ID: 21252284
[TBL] [Abstract][Full Text] [Related]
11. Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells.
Shibata T; Kan H; Murakami Y; Ureshino H; Watari K; Kawahara A; Kage M; Hattori S; Ono M; Kuwano M
Mol Cancer Ther; 2013 May; 12(5):737-46. PubMed ID: 23445612
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Menendez JA
J Cell Physiol; 2011 Jan; 226(1):52-7. PubMed ID: 20658522
[TBL] [Abstract][Full Text] [Related]
13. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
14. HER2 aberrations in cancer: implications for therapy.
Yan M; Parker BA; Schwab R; Kurzrock R
Cancer Treat Rev; 2014 Jul; 40(6):770-80. PubMed ID: 24656976
[TBL] [Abstract][Full Text] [Related]
15. miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.
De Cola A; Volpe S; Budani MC; Ferracin M; Lattanzio R; Turdo A; D'Agostino D; Capone E; Stassi G; Todaro M; Di Ilio C; Sala G; Piantelli M; Negrini M; Veronese A; De Laurenzi V
Cell Death Dis; 2015 Jul; 6(7):e1823. PubMed ID: 26181203
[TBL] [Abstract][Full Text] [Related]
16. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
[TBL] [Abstract][Full Text] [Related]
17. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
Zhu X; Wu L; Qiao H; Han T; Chen S; Liu X; Jiang R; Wei Y; Feng D; Zhang Y; Ma Y; Zhang S; Zhang J
J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
[TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
19. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
20. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
